Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Their lead product candidate, AR-301, is in Phase III pivotal trials for treating lung infections caused by S. aureus alphatoxin. The company is also developing a range of other fully human monoclonal antibodies targeting various infections, including those caused by methicillin-resistant Staphylococcus aureus, gram-negative bacteria P. aeruginosa, Acinetobacter baumannii, and respiratory syncytial virus. Additionally, they have anti-infective therapies in clinical trials for managing chronic lung infections in cystic fibrosis patients and treating non-hospitalized COVID-19 patients.

Products

• AR-301 for lung infections

• AR-320 for S. aureus infections

• AR-105 for gram-negative bacteria

• AR-101 for hospital-acquired pneumonia

• AR-401 for Acinetobacter baumannii infections

• AR-201 for respiratory syncytial virus

• AR-501 for chronic lung infections in cystic fibrosis patients

• AR-712 and AR-701 for non-hospitalized COVID-19 patients